# Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

> **NCT05639166** · PHASE2 · COMPLETED · sponsor: **Immune Biosolutions Inc** · enrollment: 200 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** IBIO123
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05639166
- **Lead sponsor:** Immune Biosolutions Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-18
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639166, "Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05639166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*